Gilead Sciences, Inc.
GILDAction· NasdaqGS· USD
L'essentiel à retenir
- • Dernier cours : 147,50 $US (cours différé)
- • Variation sur 1 an : +33,41 %
- • Type d'actif : Action
- • Place de cotation : NasdaqGS
- • Devise de cotation : USD
- • Clôture précédente : 149,05 $US
Informations
- Symbole
- GILD
- Type
- Action
- Place
- NasdaqGS
- Devise
- USD
- Clôture veille
- 149,05 $US
- Variation 1 an
- +33,41 %
More Upside Awaits for Gilead Sciences Stock. Stay Invested.
Gilead shares are up 35% since Barron’s highlighted them, but our catalysts have yet to fully play out.
Yahoo Finance · 02/10/2026 · lire l'article ↗
Gilead Sciences, Inc. (GILD) Is a Trending Stock: Facts to Know Before Betting on It
Gilead (GILD) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Yahoo Finance · 01/10/2026 · lire l'article ↗
Gilead Sciences (GILD) Declines More Than Market: Some Information for Investors
In the latest trading session, Gilead Sciences (GILD) closed at $149.45, marking a -1.21% move from the previous day.
Yahoo Finance · 30/09/2026 · lire l'article ↗
CAR T-Cell Therapy Market Forecasts Growth from $7.24B (2026) to $13.78B by 2031, Profiling Bristol-Myers Squibb, Gilead Sciences, Novartis & J&J
The global CAR T-cell therapy market is projected to grow from USD 7.24 billion in 2026 to USD 13.78 billion by 2031, registering a 13.7% CAGR. Growth is driven by rising cancer prevalence, technological advances, expanding clinical trials, and increased investment, while high costs and adverse effects remain barriers. Yescarta led the product market in 2025, hospitals were the largest end-user segment, and Asia Pacific is forecast to record the fastest growth through 2031.Dublin, Sept. 30, 2026
Yahoo Finance · 30/09/2026 · lire l'article ↗
Former Gilead CIO and CSL Chief Digital & Information Officer Mark Hill Joins Sware Board of Directors
BOSTON, September 29, 2026--Sware, Inc., the company behind the Res_Q, the AI-powered validation platform, and provider of GxP compliance solutions, today announced the appointment of Mark Hill to its Board of Directors.
Yahoo Finance · 29/09/2026 · lire l'article ↗
Small Molecule Drug Discovery - Global Strategic Business Report Forecasts Growth from $61.5B (2024) to $100B by 2030, Profiling AstraZeneca, Gilead Sciences, Merck & Pfizer
AI, computational design and high-throughput screening are accelerating discovery, while targeted therapies, outsourcing and Asia-Pacific expansion create opportunities.Dublin, Sept. 29, 2026 (GLOBE NEWSWIRE) -- "Small Molecule Drug Discovery - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering. The global small molecule drug discovery market was valued at US$61.5 billion in 2024 and is projected to reach US$100 billion by 2030, expanding at a compound annual g
Yahoo Finance · 29/09/2026 · lire l'article ↗
Titres et résumés fournis par les sources d'origine (flux Yahoo Finance). Cliquez pour lire l'article complet.
Questions fréquentes sur Gilead Sciences, Inc.
- Quel est le cours actuel de Gilead Sciences, Inc. ?
- Le dernier cours connu de Gilead Sciences, Inc. (GILD) est de 147,50 $US (cours différé, fourni à titre informatif). Cette page est mise à jour régulièrement.
- Quelle est la performance de Gilead Sciences, Inc. sur un an ?
- Sur les 12 derniers mois, Gilead Sciences, Inc. (GILD) affiche une variation de +33,41 %. Les performances passées ne préjugent pas des performances futures.
- Comment suivre Gilead Sciences, Inc. dans mon portefeuille ?
- Créez un compte gratuit sur AssetApp, ajoutez GILD à l'un de vos portefeuilles et suivez sa valeur, vos plus-values et son actualité — aux côtés de vos autres actifs.
Actifs similaires
Gilead Sciences, Inc. : suivre cet actif
Gilead Sciences, Inc. (GILD) est une action coté sur NasdaqGS en USD. Avec AssetApp, ajoutez GILD à votre portefeuille pour suivre sa valeur, vos gains latents et réalisés, et l'évolution de votre patrimoine — sans dépendre de votre courtier.
Suivre GILD gratuitement